Stockreport

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024 Received US FDA Fast Track Designati [Read more]